logo-loader

IQ-AI files patent for non-toxic MRI scan technology

Published: 03:42 22 Oct 2018 EDT

mri scanner
Recent research has highlighted the potential toxicity of gadolinium

IQ-AI Limited (LON:IQAI) has filed a patent for gadolinium-free magnetic resonance imaging (MRI) scan.

Over the past decade, research has shown the potential toxicity of gadolinium-based products and how they are retained in the body for several years.

The compounds have also been shown to potentially induce nephrogenic systemic fibrosis (NSF) in a small number of patients, particularly those with compromised kidney function.

IQ-AI, formerly known as Flying Brands, reckons it can eliminate the need for gadolinium-based contrast agents in MRI scans, saving healthcare systems money and avoiding the emerging toxicity concerns.

The firm’s invention is based on deep learning (DL) techniques – a form of artificial intelligence – using only non-contrast MR images as inputs.

“We are delighted to announce the filing of this patent,” said chief executive of IQ-AI’s operating subsidiaries, David Smith.

“We believe the potential exists to develop, for the first time, a contrast agent-free imaging technology that should generate output comparable to traditional contrast-based imaging, offering significant savings to global healthcare systems.”

He added: “We now intend to develop the technology and conduct the clinical work necessary to prepare for worldwide regulatory submissions.”

IQ-AI advances glioblastoma clinical trial, eyes phase two in 2025

Dr Jennifer Connelly, MD, the Principal Investigator (PI) of the IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) sponsored phase one clinical trial that is being conducted at the Medical College of Wisconsin, joined Proactive's Stephen Gunnion with a positive update from its treatment for recurring...

on 02/23/2024